Date

May 19, 2021

1138314455

 

UniCredit Start Lab, in collaboration with the law firm Orrick, matches the best Italian Life-Science startups, interested in pursuing growth, with a selected audience of major industry players and national and international investors

 

 

To support the propellant boost of the 'younger, more technological' research and development processes in the Italian production system, with particular reference to the life-science sector, by encouraging matches between investors and national and international corporate enterprises and the real players of the innovation ecosystem: start-ups.

 

This, in just a few words, is the goal of the "Italy Tech 2021 - Life Science event" organised by UniCredit Start Lab, in collaboration with the law firm Orrick, on Wednesday 19 May.

 

The event will kick-off with the presentations of the Life Science start-ups involved:

 

Deep Trace (Milano): company able to provide early diagnosis and predict the progression of Alzheimer's cases, through an analysis of the human brain steered by the use of Artificial Intelligence and Cognitive Computing tools

 

Iama (Genova): solution for treating brain disorders through the development of first-class drugs. The company It is testing a new drug that can significantly alleviate the learning and memory difficulties typical of Down's syndrome, as well as the more significant behavioral manifestations of the autism spectrum.

 

Prometheus (Parma): start-up which proposes Ematik, an innovative patented system for the creation of an autologous and customised medicine for veterinary use, in particular for the treatment of skin wounds.  An extension of the product's use for the treatment of ulcers and wounds on the human epidermis is planned.

 

Tensive (Milano): biomedical company pioneering the development of innovative implants, based on biodegradable materials, for breast reconstruction and enhancement. The prosthesis allows cancer patients a natural breast reconstruction with tissue self-generation.

 

Tethis (Milano): is developing a unique approach to liquid biopsy for the diagnosis of solid tumors. The solution leverages nanotechnology to innovatively manage the most critical pre-analytical steps related to blood sample preparation for subsequent analysis with digital imaging.

 

The event programme includes a speech by Bà Minuzzi (CEO of Umana, a multi-family office in California) who will analyse the main sector trends, Luca Benatti (CEO of Erydel, a biopharmaceutical company specialising in the development of products administered through patients' red blood cells) and Paolo Rizzardi (CEO of Altheia Science, a scale-up active in pre-clinical gene therapy), in a roundtable moderated by Giovanni Rizzo (Italian Angels for Biotech).